ISARNA Therapeutics GmbH

🇩🇪Germany

Country: 🇩🇪Germany

Ownership: Holding

Established: 1998-01-01

Employees: 1

Market Cap: -

Website: http://www.isarna-therapeutics.com

Clinical Trials

Phase I Dose Escalation Study to Investigate the Safety of ISTH0036 in Subjects With Glaucoma Undergoing Trabeculectomy

Phase 1

Completed

Conditions: Primary Open Angle Glaucoma

Interventions: Drug: TGF-β2 antisense oligonucleotide
Procedure: Trabeculectomy

First Posted Date: 2015-04-02

Last Posted Date: 2018-02-28

Lead Sponsor: Isarna Therapeutics GmbH

Target Recruit Count: 13

Registration Number: NCT02406833

Locations: 🇩🇪
University Hospital Magdeburg, Ophthalmology, Magdeburg, Germany
🇩🇪
Department of Ophthalmology, Johannes-Gutenberg University Mainz, Mainz, Germany
🇩🇪
University of Tuebingen, Center of Ophthalmology, Tuebingen, Germany

Safety and Tolerability of AP 12009, Administered I.V. in Patients With Advanced Tumors Known to Overproduce TGF-beta-2

Phase 1

Completed

Conditions: Melanoma
Colorectal Neoplasms
Pancreatic Neoplasms

Interventions: Drug: AP 12009

First Posted Date: 2009-02-13

Last Posted Date: 2019-02-15

Lead Sponsor: Isarna Therapeutics GmbH

Target Recruit Count: 62

Registration Number: NCT00844064

Locations: 🇩🇪
Universitätsmedizin Berlin Charité, Berlin, Germany
🇩🇪
Universitätsklinik und Poliklinik für Innere Medizin I, Halle (Saale), Germany
🇩🇪
Universitätsklinikum Schleswig-Holstein, Kiel, Germany

and more 7 locations

Efficacy and Safety of AP 12009 in Patients With Recurrent or Refractory Anaplastic Astrocytoma or Secondary Glioblastoma

Phase 3

Terminated

Conditions: Anaplastic Astrocytoma
Glioblastoma

Interventions: Drug: temozolomide
Drug: trabedersen
Drug: carmustine
Device: Drug delivery system for administration of AP 12009
Procedure: Placement of Drug Delivery System
Drug: lomustine

First Posted Date: 2008-09-29

Last Posted Date: 2014-11-14

Lead Sponsor: Isarna Therapeutics GmbH

Target Recruit Count: 27

Registration Number: NCT00761280

Locations: 🇦🇷
FLENI, Ciudad Autónoma de Buenos Aires, Argentina
🇺🇸
NJ Neuroscience Institute; JFK Medical Center, Edison, New Jersey, United States
🇺🇸
University of Rochester Medical Center, Rochester, New York, United States

and more 64 locations

Phase IIb Clinical Trial With TGF-β2 Antisense Compound AP 12009 for Recurrent or Refractory High-grade Glioma

Phase 2

Completed

Conditions: Glioblastoma
Anaplastic Astrocytoma

Interventions: Drug: AP 12009 80 µM
Drug: temozolomide or PCV
Drug: AP 12009 10 µM
Device: Drug delivery system for administration of AP 12009
Procedure: Placement of Drug Delivery System

First Posted Date: 2007-02-06

Last Posted Date: 2013-12-03

Lead Sponsor: Isarna Therapeutics GmbH

Target Recruit Count: 141

Registration Number: NCT00431561

Locations: 🇩🇪
Medizinische Klinik und Poliklinik mit Schwerpunkt Onkologie und Hämatologie, Charité Campus Mitte, Berlin, Germany
🇩🇪
Klinik und Poliklinik für Neurologie, Cottbus, Germany
🇩🇪
Universitätsklinikum Carl Gustav Carus an der Technischen Universität Dresden, Dresden, Germany

and more 33 locations

Prev
1
Next

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy